JPWO2022129254A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022129254A5
JPWO2022129254A5 JP2023536144A JP2023536144A JPWO2022129254A5 JP WO2022129254 A5 JPWO2022129254 A5 JP WO2022129254A5 JP 2023536144 A JP2023536144 A JP 2023536144A JP 2023536144 A JP2023536144 A JP 2023536144A JP WO2022129254 A5 JPWO2022129254 A5 JP WO2022129254A5
Authority
JP
Japan
Prior art keywords
diacid
cntatc
amide
aib
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023536144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554046A (ja
JP2023554046A5 (https=
JP7767428B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/086034 external-priority patent/WO2022129254A1/en
Publication of JP2023554046A publication Critical patent/JP2023554046A/ja
Publication of JP2023554046A5 publication Critical patent/JP2023554046A5/ja
Publication of JPWO2022129254A5 publication Critical patent/JPWO2022129254A5/ja
Priority to JP2025182255A priority Critical patent/JP2026031965A/ja
Application granted granted Critical
Publication of JP7767428B2 publication Critical patent/JP7767428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023536144A 2020-12-16 2021-12-15 ポリペプチド及びその使用 Active JP7767428B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182255A JP2026031965A (ja) 2020-12-16 2025-10-29 ポリペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125996P 2020-12-16 2020-12-16
US63/125,996 2020-12-16
PCT/EP2021/086034 WO2022129254A1 (en) 2020-12-16 2021-12-15 Polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182255A Division JP2026031965A (ja) 2020-12-16 2025-10-29 ポリペプチド及びその使用

Publications (4)

Publication Number Publication Date
JP2023554046A JP2023554046A (ja) 2023-12-26
JP2023554046A5 JP2023554046A5 (https=) 2024-10-24
JPWO2022129254A5 true JPWO2022129254A5 (https=) 2024-10-24
JP7767428B2 JP7767428B2 (ja) 2025-11-11

Family

ID=79287870

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023536144A Active JP7767428B2 (ja) 2020-12-16 2021-12-15 ポリペプチド及びその使用
JP2025182255A Pending JP2026031965A (ja) 2020-12-16 2025-10-29 ポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182255A Pending JP2026031965A (ja) 2020-12-16 2025-10-29 ポリペプチド及びその使用

Country Status (16)

Country Link
US (3) US20240067693A1 (https=)
EP (1) EP4263586B1 (https=)
JP (2) JP7767428B2 (https=)
KR (1) KR20230120134A (https=)
CN (1) CN116685599A (https=)
AR (1) AR124391A1 (https=)
AU (2) AU2021399076B2 (https=)
CA (1) CA3204296A1 (https=)
CL (1) CL2023001719A1 (https=)
CO (1) CO2023009066A2 (https=)
CR (1) CR20230311A (https=)
EC (1) ECSP23052600A (https=)
IL (1) IL303578A (https=)
MX (1) MX2023007288A (https=)
TW (1) TW202241933A (https=)
WO (1) WO2022129254A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240067693A1 (en) 2020-12-16 2024-02-29 Medimmune Limited Polypeptides and uses thereof
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー/エス Glp-1、gip、およびアミリン受容体の三重作動薬
WO2025147628A2 (en) * 2024-01-05 2025-07-10 Indiana University Research And Technology Corporation Dual amylin calcitonin receptor agonists
WO2025242620A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof
WO2026058194A1 (en) 2024-09-12 2026-03-19 Medimmune Limited Polypeptide dosage regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー/エス アミリン誘導体
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CN102197049B (zh) * 2008-10-21 2015-03-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
US9205135B2 (en) * 2009-09-22 2015-12-08 University Of Miami Podocyte pH modulation and uses thereof
US20140249076A1 (en) 2011-10-18 2014-09-04 Astrazeneca Pharmaceuticals Lp Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
SG10201805039UA (en) * 2013-12-13 2018-07-30 Medimmune Ltd Protease resistant peptides
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
AR116632A1 (es) 2018-10-11 2021-05-26 Intarcia Therapeutics Inc Polipéptidos análogos de la amilina humana y sus métodos de uso
WO2020225781A1 (en) 2019-05-08 2020-11-12 Auckland Uniservices Limited Peptide conjugate amylin agonists and uses thereof
US20240067693A1 (en) 2020-12-16 2024-02-29 Medimmune Limited Polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
US12054528B2 (en) Co-agonists of the GLP-1 and amylin receptors
JP2008500281A5 (https=)
EP2729493B1 (en) Novel compounds and their effects on feeding behaviour
JPWO2022129254A5 (https=)
TWI428346B (zh) 新穎化合物及其等對進食行為影響
JP7767428B2 (ja) ポリペプチド及びその使用
CN1145497C (zh) 肠胃外营养组合物及其制药用途
WO2021136296A1 (zh) 胰岛素衍生物
US8114958B2 (en) Amylin family peptides
JP2019504055A5 (https=)
US20140206615A1 (en) Glp-1 agonist and cardiovascular complications
EP2468858A1 (en) Fusion protein regulating plasma glucose and lipid, its preparation method and use
JP2018119006A (ja) 持続型インスリン分泌性ペプチド結合体の液状製剤
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
EP2029160A2 (en) Methods to restore glycemic control
JPWO2022129526A5 (https=)
EP1263458A1 (en) Lowering serum lipids
CN101578107B (zh) 泌酸调节肽类似物及其对进食行为的影响
CN121773127A (zh) 用于治疗人类疾病和病症的稳定glp-1类似物
RU2025125845A (ru) Соединения
BR122024023347A2 (pt) Coagonistas dos receptores glp-1 e amilina, formulação farmacêutica compreendendo os ditos coagonistas e uso terapêutico dos mesmos
JP2018090636A (ja) 新規化合物及び摂食行動に対するそれらの効果
MX2007005274A (en) Methods for treating obesity and obesity related diseases and disorders